Showing Results for
- Academic Journals (59)
Search Results
- 59
Academic Journals
- 59
- Search Terms:ISSN: 14655411AndISSN: 1465542XAndVolume Number: 11AndIssue Number: 1AndStart Page: 202AndDate: 2009 Revise Search
- 1From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): E Amir1 , O Freedman1 , C Simmons1 , N Miller2 , W Geddie2 , A DeBorja1 , H Maung1 , D Gianfelice3 , K Murphy3 and M Clemons1 Objective Decisions about systemic treatment of women with metastatic breast...
- 2From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): F Ricci1 , T Scala1 , M Dorkin1 , E Saralli1 , LG Capuano1 , P Picozzi1 , M Sacchi1 , R Salvatori2 , A D'Agostini2 , C De Masi3 , G Cerimoniale3 , S Frau3 , GP Fanelli3 , R Cianni3 and A Rossi4 Sentinel...
- 3From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-Reviewed
Advanced topics in array comparative genomic hybridization for diagnosis of hereditary breast cancer
Author(s): H Rassi1 Array comparative genomic hybridization (aCGH) is an efficient approach for scanning entire genomes to seek variations in genomic copy number variations, genotyping and medical genetics. It is... - 4From: Breast Cancer Research. (Vol. 11, Issue 1) Peer-ReviewedThe factors associated with the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer are poorly understood. Many studies of this subject focus on the role of molecular and genetic alterations in the...
- 5From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): T Nakayama1 , N Masuda2 , J Yamamura2 , S Kamigaki3 , T Taguchi1 , M Hatta4 and J Sakamoto4 Objective Although anthracycline is a key agent in breast cancer treatment, there is a concern that it may...
- 6From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): PF Conte1 and S Giovannelli1 In the past years, anti-angiogenic therapies have rapidly developed for many solid tumors, including breast cancer. The first phase III trial of bevacizumab in combination...
- 7From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): K Lundgren1 , K Jirström1 and G Landberg1 Objective The main focus of our study was to investigate the importance of [beta]-arrestin-1 in breast cancer and to elucidate a possible link between...
- 8From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): MTFD Vrancken Peeters1 Axillary staging is necessary since 30 to 40% of patients with curable breast cancer will have metastases in the axilla. Years ago, the most radical method of staging was performed:...
- 9From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): A Howell1 The major controversy concerning adjuvant hormonal therapy for premenopausal patients is the absence of appropriate clinical trial data to indicate the appropriate way to treat patients...
- 10From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): C Hudis1,2 The era of breast cancer as a single disease, and one-size-fits-all treatment, has passed. Hormone receptor status has allowed us to identify two phenotypic subtypes of breast cancer...
- 11From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): L Manso1 , E Ciruelos1 , A Rodríguez1 , J Diaz1 , C Mendiola1 , JA López-Martín1 and H Cortes-Funes1 Circulating epithelial tumor cells (CTCs) in peripheral blood are an ideal source for the detection of...
- 12From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): E Amir1 , OC Freedman1 , S Chia2 , T Petrella3 , S Dent4 , K Tonkin5 , I Ahmad6 , D Rayson7 , G Dranitsaris1 and M Clemons1 Fulvestrant use in heavily pretreated patients with metastatic breast cancer is...
- 13From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): E Amir1 , R Broom1 , O Freedman1 , WS Ooi1 , S Done2 , D Gianfelice3 , D Barth1 , H Kahn4 and M Clemons1 Objective The treatment of bone metastases in breast cancer patients is based on the hormone...
- 14From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): EP Winer1 Adjuvant therapy of HER2+ breast cancer has evolved dramatically over the past 4 years. It is now widely appreciated that treatment with trastuzumab, when administered concurrently or...
- 15From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): J Iglesias1 Taxanes (paclitaxel and docetaxel) are highly active chemotherapeutic agents in the treatment of breast cancer. Being hydrophobic, taxanes require solvents (Cremphor EL or polysorbate) to...
- 16From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): OC Freedman1 , E Amir1 , G Dranitsaris1 , M Dowsett2 , DEC Cole3 , H Kahn4 , F O'Malley5 , S Verma6 and M Clemons1 Despite many large randomised trials assessing adjuvant endocrine treatment for...
- 17From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): H Rassi1 The most common gene changes in breast cancer are those of the BRCA1 /BRCA2 genes. As both are large multi-exon genes, mutation screening of BRCA1 /BRCA2 is technically challenging, because each...
- 18From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): SJ Kronowitz1 , KK Hunt1 , H Kuerer1 , E Strom1 , TA Buchholz1 , JE Ensor1 , CA Koutz1 and GL Robb1 The authors previously compared the local tissue rearrangement, breast reduction, and latissimus dorsi...
- 19From: Breast Cancer Research. (Vol. 11, Issue Suppl 1) Peer-ReviewedAuthor(s): M van de Vijver1 High-throughput genetic analysis of breast cancer results in improved classification of breast cancer and can be used to identify prognostic and predictive factors. These prognostic and...
- 20From: Breast Cancer Research. (Vol. 11, Issue 1) Peer-ReviewedThrough the use of surrogate markers of efficacy, neoadjuvant studies may facilitate the implementation of new treatments into clinical practice. However, disease-free survival is the current standard outcome endpoint...